

# Medicine: encorafenib (brand name: Braftovi®)

## Resubmission

Pierre Fabre Ltd

The Scottish Medicines Consortium (SMC) has assessed encorafenib for the treatment of melanoma. It was assessed for use in combination with binimetinib to treat adult patients with advanced melanoma with BRAF V600 mutation. This document summarises the SMC decision and what it means for patients.

### What has SMC said?

After careful consideration, SMC has accepted encorafenib for the treatment of advanced melanoma as described above.

This SMC advice takes into account a confidential discount offered by the pharmaceutical company that improves the cost-effectiveness of encorafenib. In addition, SMC was able to apply a more [flexible approach\\*](#) in the assessment, as it is for a rare condition where patients are likely to have a life expectancy of less than three years with currently available treatments.

### What does SMC's decision mean for patients?

If your healthcare professional thinks that encorafenib for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland.



### What is encorafenib used for?

Encorafenib is used to treat patients with melanoma, which is a type of skin cancer. It is used to treat adult patients with advanced melanoma that cannot be removed by surgery (unresectable) or has spread to other parts of the body (metastatic). Encorafenib is used with another medicine called binimetinib in patients whose cancer cells have a specific genetic change (mutation) known as BRAF V600.

### How does encorafenib work?

In melanoma cells with the BRAF V600 mutation, the BRAF protein is overactive. This causes the cells to multiply in an uncontrolled way. Encorafenib works by blocking the BRAF protein, which helps slow the growth and development of the cancer cells.

\*<https://www.scottishmedicines.org.uk/media/4731/pace-overview-document.pdf>

## How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC consider the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- Information from patient groups about the potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of encorafenib by looking at the SMC Detailed Advice Document (SMC2238).

## More information

The organisations below can provide more information and support for people with melanoma and their families. SMC is not responsible for the content of any information provided by external organisations.

### Melanoma Action and Support Scotland (MASScot)



<http://www.masscot.org.uk>



0141 946 2017

### Melanoma UK



<http://www.melanomauk.org.uk>



0808 171 2455

You can find out more about encorafenib in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>